News | July 02, 2007

Cleveland Clinic Florida PEMF Cardiac Trial Completes Enrollment

July 3, 2007 - Ivivi Technologies Inc., a non-invasive, electrotherapeutic technology developer, announced that it has completed enrollment of 30 patients participating in a double-blind, randomized, placebo-controlled clinical trial utilizing its pulsed electromagnetic field (PEMF) technology to treat patients with ischemic cardiomyopathies conducted at The Cleveland Clinic Florida.
The trial is designed for cardiac patients who are not candidates for surgical intervention such as angioplasty, stenting or cardiac bypass surgery but will analyze the use of PEMF technology over five months on patients with ischemic cardiomyopathy. The primary objective is the improvement in regional myocardial perfusion and function as seen with a 64-slice CT scan. The secondary objective is patient improvement for angina and exercise tolerance. Data analysis and results is expected to be available by the end of 2007.
Doctors anticipate that the non-invasive application of PEMF technology may improve cardiac circulation by increasing blood flow and stimulating the growth of new blood vessels, potentially reducing the need for many invasive cardiac procedures.

For more information: www.ivivitechnologies.com


Related Content

News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
Subscribe Now